In an effort to reduce cancer health disparities among Asian-Americans, UC Davis Comprehensive Cancer Center now offers individual, in-language education and culturally sensitive materials for every Asian-American cancer patient.
Biospecimen collection among diverse populations lags far behind that of whites. In work aimed at boosting these collection rates, researchers at UC Davis and collaborators at three other institutions found that Asian, African and Hispanic Americans are open to donating specimens for research when clinicians and scientists adopt the right strategies.
For the first time, scientists have succeeded in coaxing laboratory cultures of human stem cells to develop into the specialized, unique cells needed to repair a patient’s defective or diseased bladder.
Researchers at UC Davis have found that the investigational cancer vaccine tecemotide, when administered with the chemotherapeutic cisplatin, boosted the immune response and reduced the number of tumors in mice with lung cancer. The study also found that radiation treatments did not significantly impair the immune response. The paper was published on March 10 in the journal Cancer Immunology Research, an American Association for Cancer Research (AACR) publication.
UC Davis clinicians and physicists have recommended new strategies to make computed tomography (CT) safer, including adoption of a new metric for dose measurement, ways to manage exposure protocols that differ by CT brand and specific approaches to reduce exposure during needle biopsies. The recommendations are detailed in papers published in the March issue of the Journal of the American College of Radiology (JACR).
Twenty years after Congress mandated that research funded by the National Institutes of Health include minorities, less than 5 percent of trials participants are non-white, and less than 2 percent of clinical cancer research studies focus on non-white ethnic or racial groups, UC Davis researchers have found.
A new study involving researchers from UC Davis and four other National Cancer Institute-designated cancer centers reveals important barriers that limit minority group participation in cancer clinical trials, findings that will be used to refine and launch more effective strategies to assure that more minorities benefit from clinical trials.
The hunt is on to find biomarkers that detect cancer, but it’s a challenging process. Early successes often are followed by heartbreaking failures. But now, researchers at UC Davis have verified that glycans (sugars attached to proteins) can be used to detect ovarian cancer. The study was published online in the journal Cancer Epidemiology, Biomarkers & Prevention.
Biomarkers for bone formation and resorption predict outcomes for men with castration-resistant prostate cancer, a team of researchers from UC Davis and their collaborators have found. Their study, published online in the Journal of the National Cancer Institute, also found that the markers identified a small group of patients who responded to the investigational drug atrasentan. The markers’ predictive ability could help clinicians match treatments with individual patients, track their effectiveness and affect clinical trial design.
An international team of researchers led by UC Davis in collaboration with scientists in Mexico and South Korea have taken a first step towards identifying glycans — sugars attached to proteins — that could help clinicians diagnose gastric cancer before it becomes deadly. Their research was published in the journal Cancer Prevention Research.
With a deluge of promising new drug treatments for advanced prostate cancer on the market, a new model of care is needed that emphasizes collaboration between urologists and medical oncologists, according to UC Davis prostate cancer experts.
When public health budgets are constrained, mammography screening should begin later and occur less frequently, a cost-effectiveness analysis for California’s Every Woman Counts (EWC) program concludes.
Orthopedic oncologists and surgical oncologists, who have been trained in the complex procedures required to remove sarcomas located deep in the muscles and other soft tissues of the limbs, conducted only 52 percent of these operations at 85 academic medical centers during a three year period, according to an analysis of national data by UC Davis researchers that is published online today in the Journal of Surgical Oncology.
The guideline, released jointly by the American Society for Radiation Oncology (ASTRO) and the American Urological Association (AUA), for the first time provides evidence- and consensus-based recommendations about the benefits and risks of additional cancer treatment after prostate-removal surgery.
The most recent in a series of studies from a team at the UC Davis Comprehensive Cancer Center has shown that a single molecule is at the heart of one of the most basic survival tactics of prostate cancer cells.
A team of UC Davis scientists has found that a product resulting from a metabolized omega-3 fatty acid helps combat cancer by cutting off the supply of oxygen and nutrients that fuel tumor growth and spread of the disease.
Study will help physicians calculate risk of post-surgical venous thromboembolisms. New research from the UC Davis Comprehensive Cancer Center may help clinicians determine which patients are at highest risk for post-surgical blood clots in the legs or lungs.
A natural, nontoxic product called genistein-combined polysaccharide, or GCP, which is commercially available in health stores, could help lengthen the life expectancy of certain prostate cancer patients, UC Davis researchers have found.
In the battle against breast cancer, medicine may be shooting at the wrong enemy. Much like using a weed-whacker to remove the top of lawn weeds, leaving the root behind, conventional treatments that target mature, late-acting cancer cells may miss early cells that can give rise to cancer recurrences.